Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Resistance to standard chemotherapy poses a major clinical problem in the treatment of ovarian cancer patients.